Preferences help
enabled [disable] Abstract
Number of results
2013 | 8 | 5 | 539-547
Article title

Prevalence and reasons for non-adherence to hyperlipidemia treatment

Title variants
Languages of publication
Physical description
1 - 10 - 2013
18 - 9 - 2013
  • Department of Family Medicine, Medical University of Lodz, 60 Narutowicza Str., 90-136, Lodz, Poland
  • [1] Pajak A, Wiercinska E, Polakowska M, Kozakiewicz K, Kaczmarczyk-Chalas K, Tykarski A et al. Rozpowszechnienie dyslipidemii u mezczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63:6 (supl. 4); S1–6
  • [2] Bandosz P, Flaherty M O’, Drygas W, Koziarek J, Wyrzykowski B, Rutkowski M et al. Explaining the decline in coronary heart disease mortality in Poland between 1991 and 2005. Eur Heart J. 2010, 31 (Abstract Suppl.), 167
  • [3] Sabate E (red). Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003
  • [4] Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152[Crossref]
  • [5] Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–467[Crossref]
  • [6] Wisniowska B, Skowron A. Evaluation of patients’ adherence to statins In Poland. Curr Med Res Opin. 2011; 27(1): 99–105[Crossref]
  • [7] Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009; 65(10): 1013–1024[WoS][Crossref]
  • [8] Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297(2): 177–186[Crossref]
  • [9] Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012 Jan;34(1):190–199[Crossref]
  • [10] Poluzzi E, Piccinni C, Carta P, Puccini A, Lanzoni M, Motola D et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011; 67(4): 407–414[WoS]
  • [11] Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient Prefer Adherence. 2012; 6: 323–329[Crossref]
  • [12] Vrijens B, De Geest S, Hughes DA, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J, for the ABC Project Team. A new taxonomy for describing and defining adherence to medications. Brit J Clin Pharmacol 2012; 73(5), 691–705. DOI: 10.1111/j.1365-2125.2012.04167.x[Crossref]
  • [13] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff 2011; 30(1): 91–99[Crossref]
  • [14] Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011; 32(3): 264–268[Crossref]
  • [15] DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42(3): 200–209[Crossref]
  • [16] Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010; 4(6): 462–471[WoS][Crossref]
  • [17] Ansell BJ. Not getting to goal: the clinical costs of noncompliance. J Manag Care Pharm 2008; 14(6 Suppl B): 9–15
  • [18] Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens. 1993; 11(12): 1403–1411[Crossref]
  • [19] Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, De Geest S, Dobbels F, Lewek P, Urquhart J, Vrijens B; for the ABC project team. Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis. Drugs. 2013 Apr 16. DOI 10.1007/s40265-013-0041-3 [Crossref][WoS]
  • [20] Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011; 107(11): 1662–1666[WoS][Crossref]
  • [21] Wu J, Seiber E, Lacombe VA, Nahata MC, Balkrishnan R. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes. Ann Pharmacother. 2011; 45(3): 342–349[Crossref]
  • [22] Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy. 2001; 21(5): 576–582[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.